Q3 2021 Moberg Pharma AB (publ) Earnings Call Transcript
Hello, and welcome to Moberg Pharma Q3 report for 2021. (Operator Instructions) Today, I am pleased to present CEO, Anna Ljung. Please begin your meeting.
()-
Thank you, and hello, everyone. My name is Anna Ljung. I'm the CEO of Moberg Pharma. And with me today, I also have our VP of Finance, Mark Beveridge. And we're happy to present the Q3 report that was published this morning. You can find the report on our website, and there, you will also find a PowerPoint presentation that I will use throughout this call.
Now start on Page 3 on that presentation is giving that overview of Moberg Pharma. We're a Swedish pharmaceutical company that base our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. And our lead program is MOB-015 against nail fungus. And here, we see that we have the possibility to be -- to become the global market leader within onychomycosis, targeting a global sales potential of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |